| |
ANNUAL REPORT 2021
Financial Highlights
Market Cap, DKKb
194
(2022 year-end market cap)
Revenue, DKKm
14,595
(2022)
2022 Operating Expenses, DKKm
8,238
(68% invested in R&D)
SHAREHOLDER LETTER
“Our 2030 Vision is not a reimagining of what Genmab is, but a bold expansion of what Genmab can be and how we aspire to use our innovation in antibody treatments to fundamentally transform the lives of patients with cancer and other serious diseases.”
Jan G. J. van de Winkel, Ph.D. President & CEO
Financial Review
“As we look back at 2022, the strength of Genmab’s financial profile really stands out. Our strong balance sheet, growing recurring revenues and significant underlying profitability have allowed us, and will continue to allow us, to strategically invest in our business and our pipeline.”
Anthony Pagano, Executive Vice President & Chief Financial Officer
| |
| |
GENMAB IN SHORT
Genmab is a leading international biotechnology company that creates, develops and commercializes antibody products to transform the treatment of cancer
-
6
Approved therapies incorporating Genmab innovation
-
9
Genmab-owned ≥50% investigational medicines in clinical development*
Tisotumab vedotin, epcoritamab, DuoBody®-PD-L1x4-1BB (GEN1046/BNT311), DuoBoday®-CD40x4-1BB (GEN1042/BNT312), DuoHexaBody®-CD37 (GEN3009), HexaBody®-CD38 (GEN3014), DuoBody®-CD3xB7H4 (GEN1047), HexaBody®-CD27 (GEN1053/BNT313), and GEN1056 (BNT322)
-
4
Proprietary technology platforms
DuoBody®, HexaBody®, DuoHexaBody®, HexElect®
-
40
INDs
Investigational new drug applications (INDs) filed by Genmab and/or partners, based on Genmab’s innovations and technology, since 1999
* As of December 31, 2022: Tisotumab vedotin co-developed with Seagen; epcoritamab co-development with AbbVie; DuoBody®-PD-L1x4-1BB, DuoBody®-CD40x4-1BB, HexaBody®-CD27 and GEN 1056 co-development with BioNTech; Genmab is development HexaBody®-CD38 in an exclusive worldwide license and option agreement with Janssen.
Corporate Social Responsibility
We are committed to being a sustainable, socially responsible biotech company. This commitment is anchored in our vision, core purpose and values, focused for impact through our CSR strategy, and lived every day by our team.
Get in touch
Contact our media relations team for press inquiries. If you have a general inquiry, please contact the Genmab switchboard at +45 7020 2728. We will handle your personal data in accordance with our Privacy Policy.
Marisol Peron
Senior Vice President,
Communications and Corporate AffairsTelephone: +1 609 524 0065
Email: [email protected]
777 Scudders Mill Road
Plainsboro, NJ 08536
USA
Andrew Carlsen (for IR)
Vice President,
Head of Investor RelationsTelephone: +45 3377 9558
Email: [email protected]
Kalvebod Brygge 43
1560 Copenhagen V
Denmark